Multiple Myeloma in 2023: What Patients & Caregivers Need to Know Now! | The Patient Story
34.4 هزار بار بازدید -
2 سال پیش
-
There are so many developments
There are so many developments happening in multiple myeloma! While this is wonderful, it is getting harder to keep track of all the potential updates and changes for those living with and caring for a loved one with myeloma.
The Leukemia & Lymphoma Society (LLS) and The Patient Story bring you this program out of the biggest blood cancer/disease conference every year where top doctors and researchers discuss the most important updates (American Society of Hematology, or ASH) which took place December 2022.
Long-time myeloma patient and advocate, Jack Aiello, leads this conversation with Dr. Joshua Richter, Multiple Myeloma Director for Blavatnik Family-Chelsea Medical Center at Mount Sinai and Dr. Muhamed Baljevic, Plasma Cell Disorders Research Director for Vanderbilt-Ingram Cancer Center.
Thank you to Karyopharm Therapeutics for its support of our patient education program!
Full story & transcript → https://www.thepatientstory.com/medic...
Join Our Community:
Website : https://www.thepatientstory.com/
Facebook: @ThePatientStory
Instagram: @ThePatientStory
Twitter: @patient_story
Contents of this Video:
00:00 - Intro
5:11 - What are bispecific antibodies?
7:29 - How soon will patients be able to start on bispecifics?
8:44 - When will bispecifics be available in Community Cancer Centers?
11:24 - Will bispecifics be given in the outpatient setting?
12:22 - Thoughts about patients needing hospitalization with bispecifics
15:40 - Limited duration treatment with bispecifics for relapsed/refractory myeloma patients
18:15 - Who would qualify for bispecifics?
19:36 - What is the overall takeaway for CAR T-cell therapy?
21:24 - How do you choose CAR T or bispecifics and in what order?
24:37 - What role do ‘novel therapies’ play?
25:30 - Understanding what dose is best for Selinexor
28:23 - How do we include more diverse populations in clinical trials?
#multiplemyeloma #multiplemyelomaawareness #bispecifics #CARTtherapy #CAR-T #cancer #stemcelltransplant #MMSM #ASH22 #thepatientstory #lls #myelomanews #myelomadrugs #cancerpatient #cancercaregiver
The Leukemia & Lymphoma Society (LLS) and The Patient Story bring you this program out of the biggest blood cancer/disease conference every year where top doctors and researchers discuss the most important updates (American Society of Hematology, or ASH) which took place December 2022.
Long-time myeloma patient and advocate, Jack Aiello, leads this conversation with Dr. Joshua Richter, Multiple Myeloma Director for Blavatnik Family-Chelsea Medical Center at Mount Sinai and Dr. Muhamed Baljevic, Plasma Cell Disorders Research Director for Vanderbilt-Ingram Cancer Center.
Thank you to Karyopharm Therapeutics for its support of our patient education program!
Full story & transcript → https://www.thepatientstory.com/medic...
Join Our Community:
Website : https://www.thepatientstory.com/
Facebook: @ThePatientStory
Instagram: @ThePatientStory
Twitter: @patient_story
Contents of this Video:
00:00 - Intro
5:11 - What are bispecific antibodies?
7:29 - How soon will patients be able to start on bispecifics?
8:44 - When will bispecifics be available in Community Cancer Centers?
11:24 - Will bispecifics be given in the outpatient setting?
12:22 - Thoughts about patients needing hospitalization with bispecifics
15:40 - Limited duration treatment with bispecifics for relapsed/refractory myeloma patients
18:15 - Who would qualify for bispecifics?
19:36 - What is the overall takeaway for CAR T-cell therapy?
21:24 - How do you choose CAR T or bispecifics and in what order?
24:37 - What role do ‘novel therapies’ play?
25:30 - Understanding what dose is best for Selinexor
28:23 - How do we include more diverse populations in clinical trials?
#multiplemyeloma #multiplemyelomaawareness #bispecifics #CARTtherapy #CAR-T #cancer #stemcelltransplant #MMSM #ASH22 #thepatientstory #lls #myelomanews #myelomadrugs #cancerpatient #cancercaregiver
2 سال پیش
در تاریخ 1401/10/09 منتشر شده
است.
34,414
بـار بازدید شده